Interventions targeting cognition, mood, neuroplasticity, and nervous system regulation — from medicinal mushrooms to psychedelic-assisted therapy.
Major clinical trials, FDA decisions, and what the data actually shows about psychedelics for depression.
Mori 2009 MCI RCT, Nagano 2010 anxiety/depression study, hericenone and erinacine NGF-stimulating compounds, Li 2018 Alzheimer's mouse model, Saitsu 2019 cog…
FDA-approved implanted VNS for epilepsy and depression, Tracey 2002 inflammatory reflex discovery, Koopman 2016 rheumatoid arthritis tVNS RCT, RESET-AF atria…
Slutsky 2010 discovery that Mg-threonate crosses the BBB in rats and enhances synaptic density, Liu 2015 on fear memory extinction in aging rats, the single …
Avallone 2000 establishing apigenin as a partial GABA-A receptor agonist at the benzodiazepine binding site; Viola 2005 double-blind RCT of chamomile extract…